Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2021

View Archived Issues

Recombinant HA stably presented on immunogenic liposomes improves immunogenicity in animal models

Discovery of a novel calcitonin gene-related peptide receptor antagonist azepinone series

Targeting hypoxia-induced metastatic genes shows therapeutic potential in uveal melanoma

FDA clears IND for phase I study of Protollin as treatment of AD

New glucocorticoid receptor modulators identified at Medshine Discovery

DNA-dependent protein kinase inhibitors discovered at Chengdu Baiyu Pharmaceutical

Enyo reports promising phase II data for vonafexor in patients with chronic hepatitis B

Beijing Kang Dini Pharmaceutical presents new IL-8 expression inhibitors

Jiangsu Simcere Pharmaceutical R&D discovers MAT2A inhibitors

Deuterated GC-376 variants show efficacy in model of SARS-CoV-2 infection

Addition of GEN-1 to standard NAC shows safety and efficacy in phase I ovarian cancer study

Changes in SavaDx and plasma P-tau181 confirm treatment effect of simufilam in AD

RemeGen receives Australian ethics approval for phase I trial of ADC RC-118

Topline phase II data with Sarconeos in sarcopenia

Evolutionary modeling warns of COVID-19 vaccine resistance

Trk-A inhibitor E-2511 restores cholinergic neurons in transgenic models of Alzheimer's disease

Lundbeck studies Lu-AG-06466 in phase I for fibromyalgia

Lundbeck opens phase I study of Lu-AG-09222 in headache model

China NMPA accepts IND for phase I study of CAN-103 for Gaucher's disease

U.K. MHRA clears initiation of first-in-human study of HMBD-001 in advanced cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...